Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $25.6 million.

  • Aclaris Therapeutics' Total Current Liabilities rose 3621.92% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 3621.92%. This contributed to the annual value of $31.6 million for FY2024, which is 208.06% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Total Current Liabilities stood at $25.6 million for Q3 2025, which was up 3621.92% from $26.8 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Total Current Liabilities registered a high of $31.6 million during Q4 2024, and its lowest value of $14.5 million during Q1 2021.
  • For the 5-year period, Aclaris Therapeutics' Total Current Liabilities averaged around $21.3 million, with its median value being $20.1 million (2024).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 3130.67% in 2024, then skyrocketed by 7114.53% in 2025.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Total Current Liabilities stood at $22.9 million in 2021, then dropped by 4.33% to $21.9 million in 2022, then soared by 41.09% to $31.0 million in 2023, then increased by 2.08% to $31.6 million in 2024, then fell by 18.88% to $25.6 million in 2025.
  • Its last three reported values are $25.6 million in Q3 2025, $26.8 million for Q2 2025, and $21.5 million during Q1 2025.